The negative impact of cytomegalovirus (CMV) infection on transplant outcomes warrants
efforts toward improving its prevention, diagnosis, and treatment. During the last 2 decades …

The discovery of acyclovir (ACV), a nucleoside analogue, more than 30 years ago,
represents a milestone in the management of HSV and VZV infections. The modest activity …

Cytomegalovirus (CMV) is one of the most common opportunistic infections that affect the
outcome of solid organ transplantation. This updated guideline from the American Society of …

Background Cytomegalovirus (CMV) reactivation is one of the most common infectious
complications after allogeneic hematopoietic cell transplant (HCT) and may result in …

The good clinical result of lung transplantation is constantly undermined by the high
incidence of infection, which negatively impacts on function and survival. Moreover …

Letermovir is a relatively new antiviral for prophylaxis against cytomegalovirus (CMV) after
allogeneic hematopoietic cell transplantation (HCT). CMV-seropositive HCT recipients who …

Background: Optimal prevention of late cytomegalovirus (CMV) disease is poorly defined.
Objective: To compare valganciclovir prophylaxis with polymerase chain reaction–guided …

Human cytomegalovirus (HCMV) resides latently in hematopoietic progenitor cells (HPCs).
During latency, only a subset of HCMV genes is transcribed, including one of the four virus …

Background The efficacy of different letermovir (AIC246, MK8228) doses (60, 120, and 240
mg/day) against human cytomegalovirus (HCMV) was evaluated in a recent phase 2b dose …

Antiviral therapy for cytomegalovirus (CMV) plays an important role in the clinical
management of solid organ and hematopoietic stem cell transplant recipients. However …